Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nabi seeks EU approval of StaphVax in kidney disease
The marketing authorization application (MAA) filing will be based on data from the previously completed phase III clinical trial of StaphVAX in end-stage renal disease (ESRD) patients. As
The marketing authorization application (MAA) filing will be based on data from the previously completed phase III clinical trial of StaphVAX in end-stage renal disease (ESRD) patients. As
The acquisition of Ilex creates a solid foundation for Genzyme’s growing oncology business by adding an emerging commercial presence, a robust pipeline and highly-regarded clinical development organization to
Under the agreement, PharmaBio Development will provide Cell Therapeutics (CTI) $25 million in cash and will make available $5 million in clinical services from Quintiles. In return, CTI
The agreement, originally entered into in February 2003, and amended in April 2004, has now been amended to extend the term to February 2006. Immunicon believes this project
ATL1102 is a second-generation antisense inhibitor of an immune system protein called VLA-4 (alpha-4 integrin chain; CD49d). ATL1102 is designed to block the synthesis of VLA-4 which is
This osteoarthritis (OA) collaboration will continue the work in two research programs that were initiated in the first collaboration with Pfizer that started in October 2002. The two-year
Of the 130 nasopharyngeal cancer patients in the intent-to-treat analysis, those in the combination arm were reported to have a 90.6% complete response compared to 51.5% in the
In the trial, 57% of patients who completed the study achieved a 50% or more reduction, compared with baseline, in the primary endpoint measure of disease activity one
STRIDE-4 was designed to determine whether a lower, 50mg dose of Thelin could be as effective as the 100mg dose and enrolled 98 patients in Latin America, Poland
Remicade (infliximab) is now indicated for reducing signs and symptoms in active ankylosing spondylitis (AS). This approval is the second for Remicade in the US in the past